<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002482</url>
  </required_header>
  <id_info>
    <org_study_id>CGAO-REA-01</org_study_id>
    <nct_id>NCT01002482</nct_id>
  </id_info>
  <brief_title>Computerized Glucose Control in Critically Ill Patients</brief_title>
  <acronym>CGAO-REA</acronym>
  <official_title>Impact of the Use of a Computerized Protocol for Glucose Control Named CGAOtm on the Outcome of Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier of Chartres</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Société Française d'Anesthésie et de Réanimation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier of Chartres</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine whether the use of the CGAOtm software is associated
      with a decrease in 90-day mortality when compared with the use of standard care methods for
      glucose control with target blood glucose levels inferior to 180 mg/dl. The CGAOtm software
      is designed to assist physicians and nurses in achieving tight glucose control (defined by a
      target for blood glucose levels between 80 and 110 mg/dl) in critically ill patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperglycemia in response to critical illness has long been associated with adverse outcomes.

      In 2001, the first &quot;Leuven study&quot;, a randomized controlled trial conducted in surgical
      intensive care patients comparing a strategy based on a nurse-driven protocol for insulin
      therapy in order to maintain normal blood glucose levels [80 - 110 mg/dl] with standard care
      defined at the time as intravenous insulin started only when blood glucose level exceeded 215
      mg/dl and then adjusted to keep blood glucose level between 180 and 200 mg/dl, showed a
      reduction in hospital mortality by one third.

      The results of this trial have been enthusiastically received and rapidly incorporated into
      guidelines, such as the Surviving Sepsis Campaign in 2004, and now endorsed internationally
      by numerous professional societies.

      However, subsequent randomized controlled trials have failed to confirm a mortality benefit
      with intensive insulin therapy among critically ill patients, in whom stress hypoglycemia is
      common. Moreover the Normoglycemia in Intensive Care Evaluation - Survival Using Glucose
      Algorithm Regulation (NICE-SUGAR) study, an international multicentre trial involving 6104
      patients, the largest trial of insulin therapy to date, showed a lower 90-day mortality in
      the control group targeted blood glucose levels inferior to 180 mg/dl when compared to the
      intervention group with tight glucose control [80 - 110 mg/dl].

      In addition, many studies and meta-analyses have reported high rates of hypoglycemia with
      tight glucose control. Consequently, considerable controversy has emerged as to whether tight
      glucose control is warranted in all critically ill patients especially as tight glucose
      control (without appropriate computer protocol) causes a significant increase in nurse
      workload.

      The conflicting results between the first Leuven study and the NICE-SUGAR study could be
      explained by numerous differences between the two trials : the specific method (algorithms,
      compliance of nurses and physicians with recommendations, etc) used to achieve tight glucose
      control in each randomized control trial could be a major issue.

      Several experimental and observational studies have highlighted the possible negative impact
      of glucose variability (large fluctuations in blood glucose possibly with undetected
      hypoglycemia and hypokalemia alternating with hyperglycemia) when implementing tight glucose
      control, be it due to the intrinsic properties of the algorithms used, technical factors
      (errors in measurements of the blood glucose level or lack of control over intravenous
      insulin therapy) or human factors (delay in performing glucose measurements or non respect of
      recommendations not based on clinical expertise but as a consequence of insufficient training
      inducing a lack of confidence in the algorithms by inexperienced nurses).

      Therefore, remaining concerns about the best way to achieve glucose control in the ICU reduce
      the impact of conclusions of all of the recent randomized controlled trials on tight glucose
      control : are the negative results due to the concept, tight glucose control with intensive
      insulin therapy in critically ill patients in order to reduce the toxicity of high blood
      glucose levels, or are the negative results mainly due to specific methods used for achieving
      tight glucose control ? In most cases the methods used in clinical trials were never tested
      in numerical patients according to existing and validated models (in SILICO expertise) before
      implementing them in clinical practice on real patients.

      Particularly, whether the use of a clinical computerized decision-support system (CDSS)
      designed for achieving tight glucose control in various ICU settings, and fine-tuned to
      reduce glucose variability, without increasing the incidence of severe hypoglycemia nor the
      nurse workload, has an impact on the outcome of patients staying at least three days in an
      ICU remains to be tested.

      Among the different CDSS, the CGAOtm software has been developed to standardize different
      aspects of glucose control in an ICU setting based on 1) explicit replicable recommendations
      following each blood glucose level measurement concerning insulin rates and time to next
      measurement, 2) reminders and alerts and 3) various graphic tools, trends, and individual
      on-line data aiming to increase the confidence of the nursing staff in the computer protocol
      and therefore their adherence, to reduce necessary training time, and to give physicians and
      nurses a way to control the tight glucose control process during the whole ICU stay.
      Moreover, the CGAOtm software is designed to take into account irregular sampling,
      saturations, and some precision and stability issues.

      The aim of the study is to evaluate the capability of the CGAOtm software to reduce 90-day
      mortality in a mixed ICU population of patients requiring intensive care for at least three
      days.

      Sample size and power calculations. The expected all cause 90-day mortality in the control
      group is 25 % (identical to the observed all cause 90-day mortality in the control group of
      the NICE-SUGAR trial). Considering that all cause 90-day mortality in the experimental group
      (computer protocol group) is expected to be 22 % (absolute reduction of 3 %), considering an
      alpha risk and a beta risk respectively of 0.05 and 0.20 and three intermediate analyses
      performed according to the O'Brien-Fleming design, 3,211 patients per treatment arms are
      needed and will be recruited from the participating 60 centres, all located in France.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause 90-day Mortality</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause 28-day Mortality</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Intensive Care Unit Mortality</measure>
    <time_frame>Date of discharge from the ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause In-hospital Mortality</measure>
    <time_frame>Day of discharge from the hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit Free Days</measure>
    <time_frame>28 days</time_frame>
    <description>Intensive care unit free days was 28-day-ICU-free-days i.e. was calculated by subtracting the actual ICU duration in days from 28 with patients who died at day 28 or before being assigned 0 free-days and those who had a stay in ICU of 28 days or more being also assigned 0 free-days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Spent in Blood Glucose Target</measure>
    <time_frame>Day of discharge from the ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe Hypoglycemia</measure>
    <time_frame>Date of discharge from the ICU</time_frame>
    <description>Number of patients with severe biological hypoglycemia (defined as blood glucose of 40 mg per deciliter or less)regardless of clinical signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>Date of discharge from the hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit Length of Stay</measure>
    <time_frame>Date of discharge from the ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Nosocomial Bacteriemia</measure>
    <time_frame>Date of discharge from the ICU</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2684</enrollment>
  <condition>Hyperglycemia</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>CGAO-based Glucose Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-Care Glucose Gontrol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CGAO-based Glucose Control</intervention_name>
    <description>Use of a clinical computerized decision-support system named CGAOtm designed to achieve tight glucose control in various ICU settings, and fine-tuned to reduce glucose variability without increasing the incidence of severe hypoglycemia or nurse workload.
CGAOtm is based on explicit replicable recommendations following each blood glucose measurement for insulin rates and time to next measurement, and reminders, alerts, graphic tools, trends, and individual on-line data aimed at increasing confidence of the nursing staff in the computer protocol and giving care staff a method for controlling the process during the whole ICU stay, according to a &quot;human-in-the-loop&quot; approach.
The algorithm used in the CGAOtm software for the calculation of the recommended insulin rates derived from a PID (Proportional-integral-derivative) controller, a generic control loop feedback mechanism widely used in industrial control.</description>
    <arm_group_label>CGAO-based Glucose Control</arm_group_label>
    <other_name>CGAO, LC_CGAO version1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard-Care Glucose Control</intervention_name>
    <description>Patients in the control group will receive conventional insulin therapy using the &quot;usual care&quot; protocol of each participating centre (already used in the centre before the beginning of the trial and targeting blood glucose levels inferior to 180 mg/dl).</description>
    <arm_group_label>Standard-Care Glucose Gontrol</arm_group_label>
    <other_name>Usual care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At time of the patient's admission to the ICU, the treating ICU specialist expects the
             patient will require treatment in the ICU that extends beyond the calendar day
             following the day of admission.

        Exclusion Criteria:

          -  Age &lt; 18 years or patient under guardianship.

          -  Pregnancy.

          -  Moribund patient or imminent death in the ICU (e.g. patient expected to die in the ICU
             within 24 hours).

          -  At time of the patient's admission, the treating physicians are not committed tu full
             supportive care.

          -  Patient admitted to the ICU for treatment of diabetic ketoacidosis or hyperosmolar
             state.

          -  Patient admitted to the ICU for hypoglycemia.

          -  Patient thought to be at abnormally high risk of suffering hypoglycemia (e.g. known
             insulin secreting tumor or history of unexplained or recurrent hypoglycemia or
             fulminant hepatic failure).

          -  Patient who have suffered hypoglycemia without documented full neurological recovery

          -  Patient is expected to be eating before the end of the day following admission.

          -  Patient previously enrolled in the CGAO-REA study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Kalfon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier de Chartres</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Riou, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>G.H.U. Est, C.H.U. Pitié-Salpétriêre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Djillali Annane, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>G.H.U. Ouest, Hôpital Raymond Poincaré</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Chastre, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>G.H.U. Est, Pitié-Salpétriêre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre-François Dequin, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHRU Tours</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hervé Dupont, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHRU Amiens</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carole Ichai, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHRU de Nice</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yannick Malledant, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHRU Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Montravers, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>G.H.U. Nord Bichat-Claude Bernard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>C.H.U. Hôpital Nord</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. d'Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.H.U. Nord Hôpital Jean Verdier</name>
      <address>
        <city>Bondy</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Jean Vilar</name>
      <address>
        <city>Bruges</city>
        <zip>33520</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Sainte-Camille</name>
      <address>
        <city>Bry sur Marne</city>
        <zip>94366</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. de Chartres</name>
      <address>
        <city>Chartres</city>
        <zip>28018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Châteauroux</name>
      <address>
        <city>Chateauroux</city>
        <zip>36019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Sud-Francilien - Site Corbeil</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des Cèdres</name>
      <address>
        <city>Cornebarrieu</city>
        <zip>31700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Victor Jousselin</name>
      <address>
        <city>Dreux</city>
        <zip>28012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental Les Oudairies</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.H.U. Sud Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Mantes-La-Jolie</name>
      <address>
        <city>Mantes-La-Jolie</city>
        <zip>78200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Desbief</name>
      <address>
        <city>Marseille</city>
        <zip>13002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Marseille</city>
        <zip>13291</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. de -Hôpital Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Nantes - Hôpital Laennec</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. de Nice - Hôpital Saint-Roch</name>
      <address>
        <city>Nice</city>
        <zip>06006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.H.U. Pitié-Salpétriêre</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.H.U. Nord Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. de Pau</name>
      <address>
        <city>Pau</city>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Groupe Hospitalier Sud, Hôpital Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. René Dubos</name>
      <address>
        <city>Pontoise</city>
        <zip>95301</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Bourran</name>
      <address>
        <city>Rodez</city>
        <zip>12000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Hôpitaux de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Intercommunal - Hôpital Font-Pré</name>
      <address>
        <city>Toulon</city>
        <zip>83100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.R.U. de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Carli P, Martin C. [Impact of Nice-Sugar: is there a need for another study on intensive glucose control in ICU?]. Ann Fr Anesth Reanim. 2009 Jun;28(6):519-21. doi: 10.1016/j.annfar.2009.05.002. Epub 2009 Jun 4. French.</citation>
    <PMID>19500942</PMID>
  </reference>
  <reference>
    <citation>Guerrini A; Roudillon G; Gontier O; Rebaï L; Isorni MA; Mutinelli-Szymanski P; Sorine M; Kalfon P. High glycemic variability induced by inappropriate algorithms for intensive insulinotherapy: the example of the NICE-SUGAR study. Abstract award winners: The best pre-selected abstracts of the 22th Annual Congress of the European Society of Intensive Care Medicine, 11-14 October 2009, Vienna, Austria. Intensive Care Med. 2009 Sep;35 Suppl 1:S111.</citation>
  </reference>
  <reference>
    <citation>Gontier O; Hamrouni M; Lherm T; Monchamps G; Ouchenir A; Kalfon P. The CGAO software improves glycaemic control in intensive care patients without increasing the incidence of severe hypoglycaemia nor the nurse workload. Abstracts of the 21th Annual Congress of the European Society of Intensive Care Medicine, 21-24 September 2007, Lisbon, Portugal. Intensive Care Med. 2008 Sep;34 Suppl 2:S220.</citation>
  </reference>
  <reference>
    <citation>Kalfon P; Marie C; Gontier O; Riou B. Improvement of glycaemic control in critically ill patients with the software CGAO. Abstract of the 20th Annual Congress of the European Society of Intensive Care Medicine, 7-10 October 2007, Berlin, Germany. Intensive Care Med. 2007 Sep;33 Suppl 2:S54.</citation>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2009</study_first_submitted>
  <study_first_submitted_qc>October 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <results_first_submitted>April 24, 2013</results_first_submitted>
  <results_first_submitted_qc>November 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 3, 2013</results_first_posted>
  <last_update_submitted>November 8, 2013</last_update_submitted>
  <last_update_submitted_qc>November 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier of Chartres</investigator_affiliation>
    <investigator_full_name>Dr Pierre KALFON</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>Hyperglycemia</keyword>
  <keyword>Hypoglycemia</keyword>
  <keyword>Intensive Care Unit</keyword>
  <keyword>Glucose Control</keyword>
  <keyword>Insulin</keyword>
  <keyword>Computer Protocol</keyword>
  <keyword>Metabolic Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult patients who were assumed to require at least 3 days in the ICU were eligible for inclusion. The study, carried out between October 2009 and June 2011, involved 34 ICUs (19 in academic tertiary care hospitals and 15 in community hospitals)</recruitment_details>
      <pre_assignment_details>876 participants were eligible but were excluded: 844 Had objection of the treating physician, 32 declined to participate</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CGAO-based Glucose Control</title>
          <description>Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.</description>
        </group>
        <group group_id="P2">
          <title>Standard-Care Glucose Gontrol</title>
          <description>Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1351"/>
                <participants group_id="P2" count="1333"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1336"/>
                <participants group_id="P2" count="1312"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Included twice</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Among the 2684 randomized patients, 1351 were assigned to tight computerized glucose control and 1333 to conventional glucose control. Thirty six patients were discarded from any analysis, 35 because they withdrew consent and 1 because he/she was included twice. Baseline analysis was performed only for the 2648 included and not discarded patients.</population>
      <group_list>
        <group group_id="B1">
          <title>CGAO-based Glucose Control</title>
          <description>Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.</description>
        </group>
        <group group_id="B2">
          <title>Standard-Care Glucose Gontrol</title>
          <description>Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1336"/>
            <count group_id="B2" value="1312"/>
            <count group_id="B3" value="2648"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="720"/>
                    <measurement group_id="B2" value="722"/>
                    <measurement group_id="B3" value="1442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="616"/>
                    <measurement group_id="B2" value="590"/>
                    <measurement group_id="B3" value="1206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" spread="16.2"/>
                    <measurement group_id="B2" value="61.6" spread="16.2"/>
                    <measurement group_id="B3" value="61.5" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="474"/>
                    <measurement group_id="B2" value="468"/>
                    <measurement group_id="B3" value="942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="862"/>
                    <measurement group_id="B2" value="844"/>
                    <measurement group_id="B3" value="1706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1336"/>
                    <measurement group_id="B2" value="1312"/>
                    <measurement group_id="B3" value="2648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>All-cause 90-day Mortality</title>
        <time_frame>Day 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CGAO-based Glucose Control</title>
            <description>Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.</description>
          </group>
          <group group_id="O2">
            <title>Standard-Care Glucose Gontrol</title>
            <description>Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause 90-day Mortality</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1336"/>
                <count group_id="O2" value="1312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431"/>
                    <measurement group_id="O2" value="447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause 28-day Mortality</title>
        <time_frame>Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CGAO-based Glucose Control</title>
            <description>Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.</description>
          </group>
          <group group_id="O2">
            <title>Standard-Care Glucose Gontrol</title>
            <description>Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause 28-day Mortality</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1336"/>
                <count group_id="O2" value="1312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326"/>
                    <measurement group_id="O2" value="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Intensive Care Unit Mortality</title>
        <time_frame>Date of discharge from the ICU</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CGAO-based Glucose Control</title>
            <description>Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.</description>
          </group>
          <group group_id="O2">
            <title>Standard-Care Glucose Gontrol</title>
            <description>Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Intensive Care Unit Mortality</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1336"/>
                <count group_id="O2" value="1312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302"/>
                    <measurement group_id="O2" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause In-hospital Mortality</title>
        <time_frame>Day of discharge from the hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CGAO-based Glucose Control</title>
            <description>Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.</description>
          </group>
          <group group_id="O2">
            <title>Standard-Care Glucose Gontrol</title>
            <description>Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause In-hospital Mortality</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1336"/>
                <count group_id="O2" value="1312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="376"/>
                    <measurement group_id="O2" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Care Unit Free Days</title>
        <description>Intensive care unit free days was 28-day-ICU-free-days i.e. was calculated by subtracting the actual ICU duration in days from 28 with patients who died at day 28 or before being assigned 0 free-days and those who had a stay in ICU of 28 days or more being also assigned 0 free-days</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CGAO-based Glucose Control</title>
            <description>Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.</description>
          </group>
          <group group_id="O2">
            <title>Standard-Care Glucose Gontrol</title>
            <description>Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.</description>
          </group>
        </group_list>
        <measure>
          <title>Intensive Care Unit Free Days</title>
          <description>Intensive care unit free days was 28-day-ICU-free-days i.e. was calculated by subtracting the actual ICU duration in days from 28 with patients who died at day 28 or before being assigned 0 free-days and those who had a stay in ICU of 28 days or more being also assigned 0 free-days</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1336"/>
                <count group_id="O2" value="1312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="0" upper_limit="22"/>
                    <measurement group_id="O2" value="13" lower_limit="0" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Spent in Blood Glucose Target</title>
        <time_frame>Day of discharge from the ICU</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe Hypoglycemia</title>
        <description>Number of patients with severe biological hypoglycemia (defined as blood glucose of 40 mg per deciliter or less)regardless of clinical signs</description>
        <time_frame>Date of discharge from the ICU</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CGAO-based Glucose Control</title>
            <description>Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.</description>
          </group>
          <group group_id="O2">
            <title>Standard-Care Glucose Gontrol</title>
            <description>Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Hypoglycemia</title>
          <description>Number of patients with severe biological hypoglycemia (defined as blood glucose of 40 mg per deciliter or less)regardless of clinical signs</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1314"/>
                <count group_id="O2" value="1289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <time_frame>Date of discharge from the hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CGAO-based Glucose Control</title>
            <description>Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.</description>
          </group>
          <group group_id="O2">
            <title>Standard-Care Glucose Gontrol</title>
            <description>Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1336"/>
                <count group_id="O2" value="1312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="10" upper_limit="37"/>
                    <measurement group_id="O2" value="20" lower_limit="9" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensive Care Unit Length of Stay</title>
        <time_frame>Date of discharge from the ICU</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CGAO-based Glucose Control</title>
            <description>Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.</description>
          </group>
          <group group_id="O2">
            <title>Standard-Care Glucose Gontrol</title>
            <description>Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.</description>
          </group>
        </group_list>
        <measure>
          <title>Intensive Care Unit Length of Stay</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1336"/>
                <count group_id="O2" value="1312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="5" upper_limit="18"/>
                    <measurement group_id="O2" value="8" lower_limit="4" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Nosocomial Bacteriemia</title>
        <time_frame>Date of discharge from the ICU</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CGAO-based Glucose Control</title>
          <description>Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.</description>
        </group>
        <group group_id="E2">
          <title>Standard-Care Glucose Gontrol</title>
          <description>Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1336"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>BG of 40 mg per deciliter or less accompanied with observed or suspected neurological symptoms</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="1336"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="1312"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1336"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1312"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Pierre Kalfon</name_or_title>
      <organization>CH Chartres</organization>
      <phone>003323730303073</phone>
      <email>pkalfon@ch-chartres.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

